US life sciences firm Surmodics to create 100 jobs in Galway and Eurofins Lancaster Laboratories to expand in Waterford

US life sciences technology company Surmodics has announced the creation of 100 new jobs in Ballinasloe, Co. Galway following its acquisition of local company Creagh Medical late last year.

Surmodics, which is based in Minnesota and operates in the medical devices and in vitro diagnostics sectors, plans to invest more than €7 million developing the facility in Ballinasloe and will invest a further €9.5 million in two research and development projects in Galway. There are currently 32 people employed at the former Creagh Medical plant.

“Surmodics is proud of our talented team of employees and our new state-of-the-art facility for medical device R&D and manufacturing in Ballinasloe”

Gary R. Maharaj, President and CEO, Surmodics.

The new jobs will be created over the next five years. The development is supported by the Department of Jobs, Enterprise & Innovation through IDA Ireland.

“This company is at the cutting edge of innovative life sciences research and development and the expansion of their newly acquired facility in Ballinasloe is very welcome news and a vote of confidence in the skilled Irish workforce”

Mary Mitchell, Jobs Minister

Eurofins Lancaster Laboratories announces major expansion plans to enhance its laboratory services footprint and create new jobs in Ireland

Meanwhile Eurofins Lancaster Laboratories, part of Eurofins Scientific (EUFI.PA), the world leader in bioanalytical testing, announces strategic plans for the expansion of its Dungarvan, Ireland campus, including development of a new building as well as expansion of its current facility.

Further, as a major employer in the South East of Ireland, Eurofins Lancaster Laboratories is set to increase its workforce to over 500 staff by 2021 with this investment by its parent company, Eurofins Scientific. Over 175 new jobs have been created in the past 24 months.

“This investment demonstrates Eurofins Lancaster Laboratories’ commitment to Dungarvan, and the large cluster of biopharma companies based in Ireland. Achieving increased levels of investment in regional locations is an important focus of IDA’s strategy ‘Winning – FDI 2015-2019’ and today’s announcement is an important step in that direction. I wish Eurofins every success as they continue to grow their operations in the South East Region.”

Martin Shanahn, CEO of IDA Ireland, Martin Shanahan

Tags: